Published: 16-11-2026 17:48 | Updated: 16-11-2026 17:48

AstraZeneca invests SEK 30 million in obesity research at KI

Illustration of a molecule with a DNA-helix in the background.
Illustration: Getty Images

AstraZeneca is investing just over SEK 30 million in four research projects in collaboration with Karolinska Institutet and Karolinska University Hospital. The initiative will run over the next five years and covers research into obesity, as well as kidney and liver diseases. The aim is to further strengthen Sweden’s position as an international leader in life sciences.

Karolinska Institutet, Karolinska University Hospital and AstraZeneca have an established, long-term partnership aimed at accelerating research and development in precision medicine in Sweden. AstraZeneca is now investing just over 30 million kronor to accelerate research into cardiometabolic and renal diseases.

Portrait of Annika Östman Wernerson.
Annika Östman Wernerson. Photo: Liza Simonsson

“Research of high scientific quality is crucial if we are to better understand complex diseases and develop the treatments of the future,” says KI President Annika Östman Wernerson. “By bringing together academia, healthcare and industry, we are creating a strong environment for groundbreaking translational research.”

Collaboration in a new field

This expanded collaboration aims to yield innovative discoveries in several areas that can improve patients’ health. One such area is obesity, and the obesity project represents a new field of research within the collaboration. 

By studying, amongst other things, the biological functions and significance of adipose tissue, the research aims to contribute to a deeper understanding of obesity and related metabolic diseases.

The four research projects

Research into obesity and the biology of adipose tissue
Project: Adipose tissue failure and detailed characterization of MoA of emerging weight loss drugs
Principal investigators: Professor Mikael Rydén and Docent Niklas Mejhert, Department of Medicine, Huddinge

Research into new therapeutic targets for advanced liver fibrosis and cirrhosis
Project: Identification of novel therapeutic targets to treat advanced liver fibrosis and cirrhosis
Principal investigator: Professor Stefano Romeo, Department of Medicine, Huddinge

Clinical epidemiology of chronic kidney disease
Project: Enhancing early drug development in chronic kidney disease (CKD) through clinical epidemiological studies in routine care
Principal investigators: Professor Marie Evans, Department of Clinical Science, Intervention and Technology, and Professor Juan-Jesus Carrero, Department of Medical Epidemiology and Biostatistics

Risk modelling, evaluation, and monitoring of treatment response in liver disease
Project: Integrated liver outcomes programme: Risk modelling, treatment evaluation, and response monitoring
Principal investigator: Docent Ying Shang in collaboration with Professor Annika Bergquist, Department of Medicine, Huddinge

The collaboration between AstraZeneca, KI and Karolinska University Hospital encompasses everything from research and development to clinical implementation across several therapeutic areas.

“This long-term partnership reflects our commitment to investing in research in Sweden and building on the unique cutting-edge expertise found within Swedish academia, the healthcare sector and the life sciences sector,” says Regina Fritsche Danielson, senior vice president and global head of research and early development at AstraZeneca. “Together, we can turn research into innovation and lay the foundations for the next generation of treatments.” 

From left: Joachim Spranger, Dean of Charité, Heyo K. Kroemer, CEO of Charité, Annika Östman Wernerson, President of KI, and Christophe Pedroletti, Hospital Director of Karolinska University Hospital.
Christophe Pedroletti. Photo: Fredric Möller Eklund

“As one of the world’s leading hospitals, we have both a responsibility and an opportunity to contribute to the development of the healthcare system of the future,” says Christophe Pedroletti, chief executive officer Karolinska University Hospital. “We are therefore investing heavily in integrating clinical research directly into patient care. Our collaboration with AstraZeneca is significant in this work and, consequently, for our patients.”

AstraZeneca is a global, science-led biopharmaceutical company operating in more than one hundred countries. The company focuses on the research, development, and commercialisation of prescription medicines in areas including oncology, rare diseases, cardiovascular, renal, and metabolic diseases, as well as respiratory and immunology. AstraZeneca has around 7,800 employees in Sweden and approximately 96,000 globally.

The news article is based on a press release from AstraZeneca.